June 2026 Ypsomed announced the commercial launch of its next-generation YpsoMate® 5.5 autoinjector for high-volume subcutaneous drug delivery in Europe, including the UK. The device supports biologics and high-viscosity formulations with enhanced usability and sustainability features.
March 2026 SHL Medical received the Zug Innovation Prize 2025 for its Elexy™ autoinjector and continued expanding commercialization of the platform across Europe, including the UK biopharmaceutical market. Elexy is designed for adaptable injection volumes and high-viscosity biologics, supporting next-generation self-injection therapies.
November 2025 Owen Mumford Pharmaceutical Services launched enhancements to its Aidaptus® reusable autoinjector platform, expanding compatibility with multiple syringe formats and supporting sustainable self-administration solutions for pharmaceutical partners developing biologic therapies.
September 2025 Nemera expanded its autoinjector development capabilities by strengthening services for combination products and drug-device development programs across Europe, including support for UK pharmaceutical companies developing injectable biologics.